載脂蛋白B100(APOB100)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Apolipoprotein B100 (APOB100)
Apo-B100
- 編號(hào)USEA603Hu
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍93.75-6,000ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于44.84ng/mL.
- 樣本類型serum, plasma and other biological fluids
- 下載 英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價(jià)格 ¥ 1029 ¥ 1470 ¥ 6615 ¥ 12495 ¥ 102900
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測(cè)載脂蛋白B100(APOB100)，經(jīng)檢測(cè)與其它相似物質(zhì)無(wú)明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來(lái)源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè)，因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的載脂蛋白B100(APOB100)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 95-102 | 98 |
| EDTA plasma(n=5) | 96-105 | 101 |
| heparin plasma(n=5) | 85-94 | 88 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的載脂蛋白B100(APOB100)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中載脂蛋白B100(APOB100)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 83-103% | 93-104% | 86-97% | 93-102% |
| EDTA plasma(n=5) | 86-101% | 86-104% | 88-95% | 86-102% |
| heparin plasma(n=5) | 78-101% | 84-104% | 83-94% | 80-99% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將載脂蛋白B100(APOB100)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的載脂蛋白B100(APOB100)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的載脂蛋白B100(APOB100)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的載脂蛋白B100(APOB100)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UNPA603Hu01 | 載脂蛋白B100(APOB100)天然蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPA603Hu01 | 載脂蛋白B100(APOB100)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA603Hu01 | 載脂蛋白B100(APOB100)多克隆抗體 | WB; IHC; ICC; IP. |
| UPAA603Hu02 | 載脂蛋白B100(APOB100)多克隆抗體 | ICC/IF |
| ULAA603Hu71 | 載脂蛋白B100(APOB100)多克隆抗體(生物素標(biāo)記) | IHC |
| UMAA603Hu23 | 載脂蛋白B100(APOB100)單克隆抗體 | WB; IHC |
| UMAA603Hu24 | 載脂蛋白B100(APOB100)單克隆抗體 | WB |
| UMAA603Hu25 | 載脂蛋白B100(APOB100)單克隆抗體 | WB |
| UMAA603Hu29 | 載脂蛋白B100(APOB100)單克隆抗體 | WB |
| UMAA603Hu27 | 載脂蛋白B100(APOB100)單克隆抗體 | IHC |
| UMAA603Hu21 | 載脂蛋白B100(APOB100)單克隆抗體 | WB; IHC |
| UMAA603Hu22 | 載脂蛋白B100(APOB100)單克隆抗體 | WB,IHC,ICC/IF |
| USEA603Hu | 載脂蛋白B100(APOB100)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| USCA603Hu | 載脂蛋白B100(APOB100)檢測(cè)試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| ULMA603Hu | 載脂蛋白B100(APOB100)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| PLoS One | Enhancement of Naringenin Bioavailability by Complexation with Hydroxypropoyl-β-Cyclodextrin [Plosone: 0018033] |
| Autonomic Neuroscience | Chemical sympathectomy induces arterial accumulation of native and oxidized LDL in hypercholesterolemic rats [ScienceDirect: S1566070211004152] |
| Toxicology | iTRAQ-based proteomic profiling of human serum reveals down-regulation of platelet basic protein and apolipoprotein B100 in patients with hematotoxicity induced by chronic occupational benzene exposure [ScienceDirect: S0300483X11004628] |
| Atherosclerosis | Up-reCavia (Guinea pig )lation of Hnf1α gene expression in the liver of rats with experimentally induced chronic renal failure – A possible link between circulating PCSK9 and triacylglycerol concentrations [Pubmed:26978583] |
| Proteomics Clinical Applications | Comparative mass spectrometric and immunoassay‐based proteome analysis in serum of Duchenne muscular dystrophy patients [Pubmed:26680509] |
| molecular nutrition & food research | Alleviating VLDL overproduction is an important mechanism for Laminaria japonica polysaccharide to inhibit atherosclerosis in LDLr-/- mice with diet-induced insulin resistance. [pubmed:27928899] |
| PROTEOMICS?-?Clinical?Applications | Comparative mass spectrometric and immunoassay-based?proteome?analysis?in?serum?ofDuchenne muscular dystrophy?patients. [pubmed:26680509] |
| Biosci Biotechnol Biochem.? | Choline and betaine ameliorate liver lipid accumulation induced by vitamin B6 deficiency in rats. [pubmed:27696964] |
| Journal of Nutritional?Science?and Vitaminology | Accumulation of Liver Lipids Induced by Vitamin B6 Deficiency Was Effectively Ameliorated by Choline and, to a Lesser Extent, Betaine [Pubmed: 30814419] |
| ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY | Zygophyllum album saponins prevent atherogenic effect induced by deltamethrin via attenuating arterial accumulation of native and oxidized LDL in rats [Pubmed: 32105945] |
| Ecotoxicol Environ Saf | Permethrin induced arterial retention of native and oxidized LDL in rats by promoting inflammation, oxidative stress and affecting LDL receptors, and collagen?… [Pubmed: 32911180] |
| Nat Commun | GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity [34853313] |
| Clinical Nutrition | Postprandial dyslipidemia after a standardized high-fat meal in BMI-matched healthy individuals, and in subjects with prediabetes or Type 2 diabetes [34656950] |
| Nano Research | Immunomodulatory hybrid bio-nanovesicle for self-promoted photodynamic therapy [] |
